Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.

Moreover, all 12 showed evidence that the islet cells had grafted and were ... a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from ...

Along with VX-880, it is also working on encapsulated islet cells as a treatment for T1D, although that programme remains in preclinical development. Encapsulation could mean doing away with the ...

stem cell-derived beta islet cell precursors to address type 1 diabetes without the need for chronic immunosuppression, including both encapsulated and unencapsulated approaches. The stock ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...